PK/Efficacy Issues

• PK and virologic response relationships have mainly been evaluated in antiretroviral naïve patients

  • Prior approvals with efficacy, safety and PK data have focused on naïve patients

1D. Are these relationships applicable to treatment experienced patients?

Are there cases where additional PK and/or efficacy data are necessary for different patient populations?

Previous slide

Next slide

Back to first slide

View graphic version